OBJECTIVE: To compare the effect of micro-needle knife therapy and betahistine mesilate tablets in the treatment of cervical vertigo (CV) and the influence on the mean blood flow velocity (Vm) of vertebral artery. METHODS: A total of 200 patients with CV were randomly divided into a micro-needle knife group (100 cases, 5 cases dropped off) and a medication group (100 cases, 3 cases dropped off). In the micro-needle knife group, micro-needle knife was performed on the suboccipital triangle of the atlantoaxial segment of the posterior neck, once every other day, for a total of 7-time treatment. The medication group received oral betahistine mesilate tablets, 6 mg each time, three times a day, for 14 consecutive days. The dizziness handicap inventory (DHI) scores of the two groups were observed before treatment, after treatment and during follow-up 3 months after treatment; the Vm of vertebral artery was compared between the two groups before and after treatment, and the clinical effect was evaluated during follow-up. RESULTS: After treatment and during follow-up, the DHI scores of the two groups were lower than those before treatment (P<0.001), and those in the micro-needle knife group were lower than the medication group (P<0.001). After treatment, the Vm of bilateral vertebral arteries in both groups was higher than that before treatment (P<0.05), and that in the micro-needle knife group was higher than the medication group (P<0.05). The total effective rate of the micro-needle knife group was 96.8% (92/95), which was higher than 67.0% (65/97) of the medication group (P<0.001). CONCLUSION Micro-needle knife therapy can improve vertigo symptoms and balance dysfunction, increase the mean blood flow velocity of vertebral artery in CV patients, and its clinical efficacy is better than oral betahistine mesilate tablets.
Betahistine ; Hemodynamics ; Humans ; Mesylates ; Treatment Outcome ; Vertebral Artery ; Vertigo/therapy*

OBJECTIVES: This study was designed to observe the clinical and audiologic characteristics of patients diagnosed as low tone hearing loss (LHL) and to evaluate the treatment response and prognosis. SUBJECTS AND METHODS: A retrospective chart review of 61 patients who were diagnosed with LHL was performed. Result of various audiologic studies and therapeutic responses of medication have been evaluated. Data were statistically analyzed with variables such as age, sex, interval between onset and treatment, initial hearing levels, findings of electrocochleargraphy, and initial concomitant symptoms according to their treatment response. RESULTS: Frequent chief complaints of LHL were tinnitus and earfullness. Tinnitus was usually matched at lower frequencies. Treatment with low-dose steroids, diuretics, and betahistine produced a high response rate of 79.4%. Complete response occurred in 49 of the 68 ears (72.1%) and partial response occurred in five of the 68 ears (7.4%). Fourteen of the 68 ears (20.6%) were in the non-responder group. Patients treated within 7 days after the onset of symptoms all showed complete response. Statistically significant prognostic factors affecting treatment response were age and intervals between onset and treatment (p<0.05). CONCLUSION: Patients with acutely onset tinnitus or ear fullness should be carefully evaluated and promptly treated under the diagnosis of LHL.
Betahistine ; Diuretics ; Ear ; Hearing ; Hearing Loss ; Humans ; Prognosis ; Retrospective Studies ; Steroids ; Tinnitus

Objective: To compare the effects of different intervention strategies for the management of residual dizziness following successful canalith repositioning procedure (CRP) in patients with benign paroxysmal positional vertigo (BPPV). Methods: A total of 129 BPPV patients with residual dizziness following successful CRP were recruited during January 2019 and July 2019. They were randomly assigned into three groups with 43 cases in each group: the vestibular rehabilitation group received rehabilitation training for four weeks; betahistine group was given orally 12 mg betahistine three times a day for four weeks; and the control group had no specific treatment. The primary outcomes were daily activities and social participation assessed by the Vestibular Activities and Participation measure (VAP). Secondary outcomes includedbalance function assessed by sensory organization test (SOT) and the duration of residual symptoms. Stata15.0 software was used for statistical analysis. Results: The scores of VAP in the three groups decreased over time, but a more significant decrease was found in vestibular rehabilitation group. Further paired comparison showed that the difference between the vestibular rehabilitation group and the control group was of statistical significance (B=-3.88, χ²=18.29, P<0.01), while the difference between the betahistine group and the control group was not statistically significant (B=-0.96, χ²=1.16, P=0.28). The balance function of the three groups showed a trend of recovery over time, with no significant differences between groups (χ²=1.37, df=2, P>0.05). The median duration of residual dizziness for both vestibular rehabilitation and betahistine groups was 14 days, while that of control group was 19 days, with no significant difference between three groups[Log-rank (Mantel-Cox) test; χ²=1.82, df=2, P=0.40]. Conclusion: Vestibular rehabilitation can significantly improve the daily activities and social participation function in BPPV patients with residual symptoms following successful CRP, but its effects on shortening the duration of residual symptoms and promoting the recovery of balance function remain uncertain.
Benign Paroxysmal Positional Vertigo ; Betahistine/therapeutic use* ; Dizziness ; Humans ; Patient Positioning ; Vestibule, Labyrinth

OBJECTIVETo observe the influence of betahistine on the expression of histamine H3 receptor in the medial vestibular nucleus (MVN) following unilateral labyrinthectomy (UL).

METHODSFifty-six healthy guinea pigs were randomly divided into three groups:the sham-operated group (group I), the UL group[group II, and UL+betahistine (BET) group (group III)], BET was intraperitoneally injection at 2.17 mg×kg(-1)×d(-1) for 7 days. The expression of histamine H3 receptor was analyzed by immunohistochemistry at 1 day, 3 days and 7 days after UL.

RESULTSH3 receptors were presented in the MVN and the expression of histamine H3 receptor were increased significantly in the ipsilateral MVN at 1 and 3 days after UL(P < 0.05), the change turned into the normal value at 7 days(P > 0.05). In the UL+BET group, the intensity of histamine H3 receptor was lower than that in the UL at 1 day and 3 days(4.25 ± 0.71, 3.50 ± 0.92 vs 5.75 ± 0.71, 5.50 ± 0.93, P < 0.05). However, the changes turned into the normal values at 3 and 7 days (P > 0.05).

CONCLUSIONSThe early stage of the vestibular compensation process may be associated with the change of H3 receptor expression in MVN. In the UL+BET group the histamine H3 receptor recovered quickly.

Animals ; Betahistine ; metabolism ; Ear, Inner ; Guinea Pigs ; Otologic Surgical Procedures ; Receptors, Histamine H3 ; metabolism ; Vestibular Nuclei ; metabolism ; Vestibule, Labyrinth ; surgery

OBJECTIVE: To compare the effectiveness and safety of Betahistine dihydrochloride (in beta cyclodextrin) with Betahistine dihydrochloride in treating patients with vertigo.
DESIGN/METHODS: This was a randomized, open label study enrolling 68 patients, ages 18 to 65 years old, diagnosed clinically with vertigo.
RESULTS: Sixty two patients completed the study. EEV scores of both groups continuously decreased to similar levels. EEV scores significantly deceased from baseline to week 4. In group A patients, EEV scores decreased from 9.81+/- 3.73 at baseline to 2.39 +/- 3.46, p<.001; similarly, in group B patients, EEV scores fell from 12.32 +/- 3.61 to 2.32 +/- 2.32 +/- .48, p
Group A patients reported 2.6 +\- 2.9 side effects while Group B patients reported 2.7 +/- 2.5 side effects (p=0.92). There were more patients who experienced vomiting, abdominal pain, nausea, vomiting and/ or diarrhea in Group B patients (8/32 in Group A vs 16/30 in Group B, p=0.022).
CONCLUSION: Betahistine dihydrochloride with beta cyclodextrin and Betahistine dihydrochloride alone are both effective in reducing the symptoms of dizziness from vertiginous syndromes. Betahistine dihydrochloride with beta cyclodextrin appears to have less gastrointestinal side effects than Betahistine dihydrochloride alone.

Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Young Adult ; Vertigo ; Safety ; Betahistine ; Dizziness ; Nausea ; Syndrome ; Vertigo ; Vomiting ; Beta-cyclodextrins

OBJECTIVES: Mèniére's disease is one of the most common causes of episodic vestibular syndrome that shows symptom complexes of recurrent vertigo, hearing loss, tinnitus and ear fullness. Isosorbide (Isobide) is a osmotic diuretics which has been used for Meniere's disease to reduce the endolymphatic pressure. The purpose of this study was to evaluate the efficacy of isosorbide in the treatment of Mèniére's disease by comparing the combined therapy of isosorbide and betahistine (Meniace) to betahistine only. METHODS: Among 220 patients enrolled with Mèniére's disease from 9 centers, 187 patients completed this clinical study. Patients were randomly subjected either to betahistine alone therapy at dose of 6 mg three times a day (n=97) or to combined therapy with isosorbide (dose of 30 mL three times a day) and betahistine (n=90) for 12 weeks. Two groups were compared at 4 and 12 weeks after treatment on frequency of vertigo, hearing level (pure tone audiometry, speech audiometry), electocochleography (ECoG), tinnitus (Tinnitus Handicap Inventory, THI) and quality of life (Korean functional level scale, Korean dizziness handicap inventory). RESULTS: During first 4 weeks after treatment, the frequency of vertigo was not reduced in either betahistine alone therapy group or combined therapy group. However, between 8 and 12 weeks, the frequency of vertigo was significantly reduced in either group, and in the combined group frequency of vertigo was more significantly reduced than in the betahistine alone therapy group (p=0.041). The hearing level, ECoG, tinnitus and quality of life was not significantly different between two groups. CONCLUSION: Isosorbide and betahistine combined therapy were more effective for vertigo control than betahistine alone therapy. Isosorbide is an effective diuretic in vertigo control in definite Mèniére's disease.
Audiometry, Speech ; Betahistine ; Clinical Study ; Diuretics, Osmotic ; Dizziness ; Ear ; Hearing ; Hearing Loss ; Humans ; Isosorbide ; Meniere Disease ; Quality of Life ; Tinnitus ; Vertigo

OBJECTIVETo determine whether Betahistine mesilate is effective in treating tinnitus.

METHODSRandomized, prospective, double-blind, controlled trial was used in our study. The study group consisted of 60 adult patients who consulted our outpatient clinic complaining of subjective tinnitus, excluded objective tinnitus and the patients who had tinnitus caused by obvious diseases, such as outer and middle ear diseases. Thirty patients were given Betahistine mesilate and Flunarizine Hydrochloride as an experimental group, 30 patients were given Vitamin B6 and Flunarizine Hydrochloride as a control group. After a week of treatment the efficacy of the medicines in two groups was observed. Tinnitus questionnaire was performed before the treatment, and pure tone audiogram, tinnitus pitch and loudness matching were performed both in the beginning and at the end of the treatment.

RESULTSCompletion of treatment, tinnitus loudness matching assessment showed that the efficacy of the Betahistine mesilate group was better then the control group. The efficacy of treatment was respectively 65.5% by per protocol (PP) and 63.3% by intend to treat (ITT) in the Betahistine mesilate group and 39.3% by PP and 36.7% by ITT in the control group. The difference of tinnitus loudness improvement rate between the experimental group and control group was statistically significant. But the subjective tinnitus improvement rate showed no difference between two groups. There were not serious side effects in the two groups.

CONCLUSIONSBetahistine mesilate can be a choice for tinnitus treatment clinically. Further studies of larger series and placebo-controlled trial are needed.

Adolescent ; Adult ; Aged ; Betahistine ; therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Flunarizine ; therapeutic use ; Humans ; Middle Aged ; Prospective Studies ; Tinnitus ; drug therapy ; Treatment Outcome ; Young Adult

OBJECTIVE: To evaluate the clinical effectiveness and safety of Sanchi Tong Shu capsule in the treatment of common aural vertigo. METHOD: A multi-center randomized controlled trial was designed to study 206 vertigo patients who were randomly allocated into one of the two groups. One group was treated with Sanchi Tong Shu capsule for 14 days, another group was treated with betahistine mesilate tablets for 14 days. RESULT: The clinical effectiveness rates of the two groups were 84.86% and 90.92% respectively according to FAS analysis and 84.76%, 90.92% respectively according to PPS analysis. No statistic significance difference was found between the two groups (P > 0.05). After 14 days treatment, total DHI and all the subsection (including body, emotion and function) scores of the two groups were all decreased compared with treatment before (P < 0.01). Compared the difference value of the total DHI and subsection scores before and after treatment, the two groups have no difference (P > 0.05). The adverse effective rate of the two groups were 3.29% and 7.84% respectively and there was no statistic difference between the two groups (P > 0.05). CONCLUSION Sanchi Tong Shu capsule is a safe and effective drug for the treatment of common aural vertigo.
Adolescent ; Adult ; Betahistine ; therapeutic use ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Male ; Meniere Disease ; drug therapy ; Middle Aged ; Phytotherapy ; Treatment Outcome ; Young Adult

To explore the characteristics and influenced factors associated with the onset of vertigo disease, analysis of 3 719 cases of hospitalized patients with vertigo disease from the real world. Analysis the date of patients diagnosed with vertigo disease from the hospital information system of 19 grade-III class-A hospital from 2004 to 2011, include general information, the doctor's advice, other diseases combined, diagnostic information and the relationship with the onset of 24 solar terms, and the treatment drugs. The median age of hospitalized patients with vertigo disease was 59, the number of women (65.91%) was more than men (34.09%), manual workers (85.32%) were the majority career, most patients (81.63%) condition were general by the time they were hospital admission, patients more like admitted to neurologist (70.34%) when they first time to outpatient serves, hospitalization days were in 8-14 days (46.65%), 46.04% of the patients in the hospital total cost is in 5 000 RMB to 10 000 RMB, 73.86% of patients paid by National Health Medical Insurance. Hypertension (20.79%) was the most common underlying health problems, The most common syndromes was deficiency of liver-Yin and kidney-Yin(44. 21%) , followed by hyperactivity of liver-yang, disease of phlegm turbidity in mongolia and deficiency of Qi and blood. There were more deficiency syndrome and less excess syndrome. The highest rate of hospital admission solar terms in 2009 was the insects awaken throttle (5.21%), In 2010, the highest rate solar terms of hospital admission was the rain throttle (6.14%). The most frequently used traditional Chinese medicine was gastrodine injection (20.55%), the most frequently used western medicine for betahistine (10.19%), gastrodine injection was the most traditional Chinese medicine that combination with other western medicine. Hypertension was the most underlying health problems in the patients with vertigo disease in the real world, although the mental factors should also be attention. Liver was the most closely internal organs with vertigo, and solar terms in spring was the highest-frequency time. Gastrodine injection was the most commonly used traditional Chinese medicin in clinical to treat vertigo diserse, the therapeutic regimen combining with traditional Chinese and western medicine has more advantages. We should pay more attention to the guidance of Chinese medicine "syncretism between heaven and man", to keep up with the rhythm of change, adapt to the changes in the human body growth and decline of the Yin and Yang, by adopting the method of syndrome differentiation in traditional Chinese medicine to prevention and treatment vertigo disease.
Adolescent ; Adult ; Aged ; Benzyl Alcohols ; therapeutic use ; Betahistine ; therapeutic use ; Diagnosis, Differential ; Female ; Glucosides ; therapeutic use ; Humans ; Male ; Medicine, Chinese Traditional ; methods ; Middle Aged ; Vertigo ; diagnosis ; drug therapy ; epidemiology ; Young Adult

OBJECTIVETo evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV).

METHODSNinety patients with VBIV were randomly divided into two groups; 45 patients (the treated group) were treated with YXDM and BHI intravenous dripping, once a day for 14 days. Another 45 patients (control group) were treated with Xueshuantong and BHI intravenous dripping, once daily for 14 days. The clinical syndromes and the index of the transcranial Doppler (TCD) and hemorheology were observed.

RESULTSThe total effective rate was 100% in the treated group, which was better than that in the control group 90.5%, (P < 0.05). The indexes of TCD and hemorheology in the treated group were obviously improved after treatment, (P < 0.01).

CONCLUSIONYXDM combined with BHT injection had better effect in treating patients with VBIV is an ideal drug for VBIV.

Adult ; Aged ; Aged, 80 and over ; Betahistine ; administration & dosage ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Hemorheology ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Treatment Outcome ; Ultrasonography, Doppler, Transcranial ; Vasodilator Agents ; administration & dosage ; Vertebrobasilar Insufficiency ; complications ; diagnosis ; drug therapy ; Vertigo ; drug therapy ; etiology